MediPines AGM100® Gas Exchange Measurements Validated Against ABGs (Arterial Blood Gases)

12 May 2020 Medical

Study Published in CHEST Validates MediPines AGM100® Non-invasive Pulmonary Gas Exchange Measurements with Arterial Blood Gases Under Hypoxic Conditions

ORANGE COUNTY, Calif., May 12, 2020 /PRNewswire/ — A collaborative of international researchers, led by Dr. Phil Ainslie of the University of British Colombia (UBC), published the results of extensive research on the reliability of the MediPines AGM100®, a non-invasive pulmonary gas exchange monitor, under various hypoxic conditions of exercise and extreme physiology.  The pivotal study, conducted by  global medical researchers and physicians from the University of British Columbia (Canada), Duke University (US), and Bangor University (UK), was published in the April edition of the leading respiratory journal, CHEST: View Abstract.  https://doi.org/10.1016/j.chest.2020.04.017 

MediPines Summary of Ainslie Study as Published in CHEST

Pulmonary gas exchange measurements provide medical staff with critical information on how well the lungs are functioning.  Traditionally, the most common method of measuring pulmonary gas exchange efficiency is through an arterial blood gas (ABG) and involves comparing those values to an estimate of the lung oxygen level using various assumed lung level values, a process which is both invasive, time consuming, and fraught with logistic challenges.  The new innovative method directly measures the lung’s oxygen and carbon dioxide levels from exhaled gas sampling method and compares them to the calculated blood oxygen level, adjusted for Bohr effect.

The validation of a non-invasive approach to measuring pulmonary gas exchange provides healthcare workers with an important tool that rapidly delivers actionable, point-of-care information about how well a patient’s lungs are functioning.  This is especially important during a respiratory pandemic like COVID-19 which requires rapid and frequent pulmonary assessments to triage patients and titrate therapy.  The medical community and researchers now have an alternative to traditional pulmonary gas exchange measurement methods.

“Given the limitations of the traditional invasive arterial blood gas approach, we used the non-invasive AGM100® to study healthy volunteers at rest and in hypoxia during progressive exercise in order to compare the validity and reliability of the two methods. The design has implications for those exercising in low oxygen tension environments, including those with pre-existing lung or cardiovascular disease,” stated Dr. Phil Ainslie, Canada Research Chair and Co-Director of the Centre for Heart lung and Vascular Health, School of Health and Exercise Sciences at the University of British Columbia, Canada.

The study found very high correlations (R2=0.97; p<0.001) between the MediPines non-invasive arterial blood oxygen level, gPaO2™, and blood gas obtained PaO2, under conditions of rest at room air, hypoxic rest, and hypoxic exercise.  The study also found a strong relationship between PaOat hypoxic rest and exercise (R2=0.68; p<0.001).

“This is a major advance in our understanding and validation of the non-invasive approach to measuring gas exchange efficiency, as built on multiple clinical studies conducted at the UC San Diego School of Medicine,” stated Dr. John B. West, global authority on respiratory physiology and author of numerous papers and textbooks on this topic.

“It is a tremendous milestone in respiratory medicine to have our technology validated by a global team of renowned respiratory scientists and researchers from the University of British Columbia, Duke University, and Bangor University.  Now physicians and clinicians have access to a rapid, noninvasive method to comfortably support their respiratory diagnosis and treatment decisions to improve patient care, especially in light of the current infectious respiratory disease outbreak, when gas exchange measurements are vital in decision making and where healthcare resources are scarce,” said Steve Lee, CEO of MediPines.

The MediPines AGM100®

The MediPines Gas Exchange Monitor, AGM100®, is a portable device used to rapidly assess a patient’s respiratory status, non-invasively. It is the first technology of its kind to integrate a comprehensive set of critical parameters and innovative respiratory measurements analyzed from a patient’s normal breathing sample in a simple, easy-to-administer breathing test, within a few minutes.

About MediPines

MediPines Corporation is focused on innovative devices for respiratory assessment and management. Our mission is to advance respiratory medicine by providing physiology-based, non-invasive respiratory devices that empower health care providers to advance the quality and operating efficiency of medical care.

SOURCE MediPines

Related Links

MediPines AGM100 Authorized for COVID-19 Emergency by Health Canada

28 Apr 2020 Medical

NEWS PROVIDED BYMediPines 

Apr 28, 2020, 13:16 ET


ORANGE COUNTY, Calif., April 28, 2020 /PRNewswire/ — Health Canada, the regulatory agency governing medical devices in Canada, has authorized the emergency importation and sale of the MediPines AGM100®, a pulmonary gas exchange monitor to help combat the COVID-19 pandemic in Canada. 

The MediPines AGM100® is a non-invasive, portable respiratory medical device used to rapidly assess a patient’s respiratory status and impairment. The device helps clinicians to quickly triage a patient’s respiratory impairment, which is critical to both disease management and hospital workflow.

Health Canada’s decision comes amid an increase in COVID-19 cases in Canada, which require close respiratory monitoring. As of April 28th, Canada reported 49,616 cases of COVID-19 and 2,841 deaths, according to data tracked by Johns Hopkins University. 

“We are currently using the MediPines AGM100® to allow medical staff to quickly get respiratory impairment readings without having to expose patients to more invasive and logistically complicated procedures,” stated Toronto area emergency physician, Dr. Oswaldo Ramirez.

According to Dr. Philip Ainslie, Professor and Canada Research Chair, and Co-Director for the Centre of Heart, Lung, & Vascular Health at the University of British Columbia, “We have extensively used and validated the MediPines AGM100® in numerous physiological and clinical scenarios. It provides a safe, reproducible and valid measure of non-invasive pulmonary gas exchange.”

“We understand the gravity of the situation faced both in the United States and by our Canadian colleagues, and have ramped up production to meet the increasing COVID-19 demand for our non-invasive gas exchange monitors in an effort to ensure that frontline healthcare workers have the tools they need to combat this pandemic,” stated Steve Lee, CEO of MediPines.

The MediPines AGM100®

The MediPines Gas Exchange Monitor, AGM100®, is a portable device used to rapidly assess a patient’s respiratory status, non-invasively. It is the first technology of its kind to integrate a comprehensive set of critical parameters and innovative respiratory measurements analyzed from a patient’s normal breathing sample in a simple, easy-to-administer breathing test, within a few minutes.

For an explanation of use in COVID-19 see the panel discussion video: 

About MediPines

MediPines Corporation is focused on innovative devices for respiratory assessment and management. Our mission is to advance respiratory medicine by providing physiology-based, non-invasive respiratory devices that empower health care providers to advance the quality and operating efficiency of medical care.

For more information contact Carissa Drews at MediPines: (949) 398-4670 or info@medipines.com

SOURCE MediPines

Related Links

MediPines Obtains International MDSAP ISO 13485 Medical Device Certification

9 Apr 2020 Medical

ORANGE COUNTY, Calif., April 9, 2020 /PRNewswire/ — MediPines Corporation announces that it received the Medical Device Single Audit Program certification, MDSAP ISO 13485:2016 certification for Medical Device and Quality Management Systems. MediPines Corporation is the manufacturer of portable respiratory monitoring devices designed to provide real-time, clinically actionable data.  

ISO 13485:2016 is an internationally recognized quality standard developed to ensure the consistent design, development, production, installation and sale of medical devices. To be certified, organizations must pass a rigorous audit that demonstrates the company’s ability to provide medical devices and related services that consistently meet customer and regulatory requirements.

The Medical Device Single Audit Program (MDSAP) was developed as a global initiative to allow third-party auditors to conduct a single audit of a medical device manufacturer that covers ISO 13485:2016 and their respective regulatory requirements. There are currently five countries participating in MDSAP: USA, Canada, Australia, Japan, and Brazil.

Building on top of implementing Good Manufacturing Practices (cGMP), as defined by the US FDA requirements for registered manufacturers, and rigorous requirements set by the California Department of Public Health for medical device manufacturing licenses in 2019, MediPines continues to expand its scope to include global quality standards to provide the highest quality medical devices to the healthcare community.

“Our MDSAP and ISO 13485 certification demonstrates MediPines’ company-wide commitment to the rigorous organizational standards and recognition of our state-of-the-art medical device manufacturing operation.  MediPines is committed to patient safety and product reliability,” stated Steve Lee, CEO of MediPines.

The MediPines AGM100® 

The MediPines Gas Exchange Monitor, AGM100® , is a portable device used to rapidly assess a patient’s respiratory status, non-invasively.  It is the first technology of its kind to integrate a comprehensive set of critical parameters and innovative respiratory measurements analyzed from a patient’s normal breathing sample in a simple, easy-to-administer breathing test, within a few minutes. 

AGM100 is currently being used to triage and assess COVID-19 patients.   

About MediPines

MediPines Corporation is the manufacturer of portable respiratory devices designed to provide real-time, clinically actionable data.  MediPines’ mission is to advance respiratory medicine by providing physiology-based, non-invasive respiratory devices that empower healthcare providers to advance the quality and operating efficiency of medical care.

https://www.prnewswire.com/news-releases/medipines-obtains-international-mdsap-iso-13485-medical-device-certification-301038433.html

COVID-19 Patients Being Triaged and Assessed Using 2 Minute Breath-Based Gas Test

6 Apr 2020 Medical

ORANGE COUNTY, Calif., April 6, 2020 /PRNewswire/ — Innovative hospitals across North America are responding to the COVID-19 pandemic and the upsurge of patients with a revolutionary breath-based gas test to support faster patient assessment, triage, and treatment decisions. The medical device uses advanced technology and proven medical methods to measure a patient’s degree of respiratory impairment. The new FDA cleared, portable gas exchange monitor, MediPines AGM100®, is effectively helping frontline healthcare workers to quickly triage and make decisions on how to treat COVID-19 patients (video).

“Our doctors and nurses are counting on this quick respiratory test to help them both identify patients that need escalated care, such as who needs to be admitted, and who needs ventilator support, while they wait for COVID-19 diagnostic test results to arrive, which unfortunately are taking days to get,” stated Dr. Oswaldo Ramirez, Emergency Physician at a leading North Eastern hospital.  

The MediPines AGM100® outputs a unique “breathing gas-based” measurement that can provide immediate respiratory data after the patient breathes into a breathing tube for less than two minutes.  Complicated or invasive or procedures are not required. The AGM100 rapidly provides measurements, such as Oxygen Deficit, that help clinicians assess the extent of a patient’s respiratory impairment.  This has proven to be especially beneficial to healthcare workers trying to prioritize limited resources in the context of COVID-19, enabling high-risk patients to receive the appropriate level of care and attention. 

The device uses a disposable breathing circuit with a mouthpiece designed to limit pathogen exposure. These features are highly important to the safety of both patients and frontline healthcare workers in order to prevent the spread of disease.

“The AGM100® is helping our medical team to better diagnose the severity of a patient’s respiratory symptoms in under a few minutes, while minimizing pathogen exposure to our valuable health care workers,” according to Dr. Ramirez.

About MediPines: MediPines is a California based manufacturer of portable respiratory monitoring devices designed to provide real-time, clinically actionable data. MediPines has released a statement of guidance on the use of the MediPines AGM100® during the COVID-19 pandemic: https://www.medipines.com/resources/.

MediPines Releases COVID-19 Statement of Guidance for Pulmonary Gas Exchange Monitoring

MediPines, in Orange County, California, is a medical device manufacturer that focuses on respiratory diagnostics and therapeutic management solutions. MediPines provides medtech solutions for respiratory screening, diagnostics, and management. (PRNewsfoto/MediPines)

NEWS PROVIDED BY MediPines 


ORANGE COUNTY, Calif., March 12, 2020 /PRNewswire/ — MediPines Corporation, in keeping with their mission of advancing respiratory medicine, has released a statement of guidance on the use of the MediPines Gas Exchange Monitor (AGM100®) in the monitoring of patients that have symptoms of suspected COVID-19 or other respiratory infections. The guidance was developed in collaboration with leading respiratory experts, and provides best practices, instructions, and clinical rationale.

The CDC recently outlined emergency warning signs for COVID-19 “including difficulty breathing or shortness of breath, persistent pain or pressure in the chest,” among other potential symptoms. Furthermore, it is estimated that approximately 90% of patients hospitalized with COVID-19 develop pneumonia or other lower respiratory tract complications which results in inefficient pulmonary gas exchange.

The AGM100® is the first and only non-invasive device that allows comprehensive quantification of pulmonary gas exchange deficiencies associated with these types of symptoms, and thus has unique advantages in providing rapid measurements at multiple time periods over the progression of the disease.  The device and guidelines may assist clinicians in the implementation CDC and WHO recommendations, as well as recommendations provided by other health authorities.

About MediPines:

MediPines Corporation, based in Orange County, California is the manufacturer of breakthrough, portable respiratory monitoring devices designed to provide real-time, clinically actionable data.  

SOURCE MediPines

Related Links

https://www.prnewswire.com/news-releases/medipines-releases-covid-19-statement-of-guidance-for-pulmonary-gas-exchange-monitoring-301022611.html

MediPines a Featured Innovator at Emerging Medtech Summit 2020

30 Jan 2020 Medical

ORANGE COUNTY, Calif., Jan. 29, 2020 /PRNewswire/ — MediPines Corporation announces its selection as a top medtech innovator at the Emerging Medtech Summit 2020. The event takes place February 18-20th, 2020 at the Ritz Carlton Laguna Niguel and features top strategists, investors, and innovators. MediPines CEO and founder, Steve Lee, will address the summit on February 18th in the afternoon and is meeting with institutional investors throughout the duration of the event.

MediPines will highlight its first commercially available respiratory medical device, the AGM100®. The AGM100® is the first portable and noninvasive respiratory device that measures pulmonary gas exchange, which is the primary function of the lungs. The device measures the degree of impaired gas exchange, along with other established respiratory parameters, within a few minutes, using an exhaled breath sampling method. The clinical applications and provider value are broad and promising. The device received FDA clearance in 2019, and it is currently utilized in a variety of clinical settings, including hospitals and outpatient clinics.

Over 30 million Americans, globally 350 million, suffer from respiratory illnesses such as COPD (chronic obstructive pulmonary disease) and new emerging respiratory diseases. There are increasing healthcare shortages and over 70 million baby boomers retiring at a rate of 10,000 per day, many of whom suffer from respiratory illness due to aging and environmental factors. “Our hope is that the technological advances we are making can help address these rising healthcare challenges,” stated Lee.

About MediPines

MediPines Corporation, based in Orange County, California, is a pioneering medical device company established to advance respiratory medicine. MediPines was launched in 2015. The MediPines portable gas exchange monitor, AGM100® is the first FDA 510(k) cleared, commercially available portable respiratory medical device that measures oxygen and carbon dioxide exchange within the lungs.

For more information, visit https://medipines.com/.

Corporate Contact:

Carissa Drews
Marketing and Communications
949.398.4670
carissa@medipines.com

SOURCE MediPines

Related Links

For more go to:

https://www.prnewswire.com/news-releases/medipines-a-featured-innovator-at-emerging-medtech-summit-2020-300995328.html

MediPines Oxistimulator® Demonstrates Reduced Oxygen Desaturations in Postoperative Patients

20 Nov 2019 Medical

Positive Clinical Trial Results Published

https://www.prnewswire.com/news-releases/medipines-oxistimulator-demonstrates-reduced-oxygen-desaturations-in-postoperative-patients-300960352.html

ORANGE COUNTY, Calif., Nov. 19, 2019 /PRNewswire/ — MediPines announces the publication of the positive clinical study results on Oxistimulator®, a breakthrough technology designed to reduce postoperative hypoxemia in patients at-risk for Obstructive Sleep Apnea (OSA).  The study demonstrated that the Oxistimulator technology decreases the duration and magnitude of hypoxemia, often referred to as oxygen desaturations. 

MediPines Oxistimulator®

The Oxistimulator is designed to continuously monitor patient oxygenation levels and reduce desaturations automatically.  Whenever dangerous oxygen levels are detected, the Oxistimulator provides an immediate therapeutic response, a mild electrical stimulation, which is just enough to reverse the deterioration without harm or discomfort to the patient.

Current pre-operative screening practices have been shown to miss nearly 50% of patients with OSA. OSA places patients at-risk for serious postoperative desaturation events such as reductions in blood oxygen levels, which can lead to complications prolonging patient hospitalization, and in some cases, even death.  Currently, the burden of catching and reducing hypoxemia after surgery falls on the clinical staff, such as nurses, who manually intervene when they see a desaturation; however, this manual process has been demonstrated to be sub-optimal, resulting in patients experiencing more and longer desaturations than necessary.

Study Results

The study was a randomized, double-blind, controlled trial of 106 post-operative patients at a major medical institution spanning multiple years.

The treatment group (with device) experienced a shorter duration of SpO2 <90% (median 0.0 seconds vs 19.1 seconds; p=0.01) compared to the control group (inactive placebo device), with no adverse events reported due to the mild electrical stimulation provided by the active device.

“Oxistimulator represents a breakthrough in the way that it empowers clinicians to automate their clinical response.  Faster response means that patients spend less time in the hypoxemia danger zone.  This is a novel solution to a serious clinical problem, and we are fortunate to be partnering with outstanding clinical partners to prove the clinical safety and efficacy as we bring this technology to market,” stated Steve Lee, CEO of MediPines.

Study results were published in the Canadian Journal of Anesthesia.  Oxistimulator has not yet been approved by the FDA and is not available for commercial sale.

About MediPines:

MediPines is based in Orange County, California and manufacturer of the FDA 510(k) cleared AGM100®. The company focuses on respiratory diagnostics and therapeutic management solutions.

SOURCE MediPines

MediPines AGM100® Launched for Perioperative Screening at 2 Leading Medical Centers

10 Sep 2019 Medical

NEWS PROVIDED BY MediPines 

Sep 10, 2019, 13:33 ET


ORANGE COUNTY, Calif., Sept. 10, 2019 /PRNewswire/ — MediPines Corporation in Orange County, CA announces the launch of the MediPines Gas Exchange Monitor (AGM100) in two major East and West Coast hospitals. The AGM100 is being deployed to support screening and stratification of surgical patients for risks in perioperative settings. Postoperative pulmonary complications (PPC) are common and recent studies suggest that they occur in 33% of high-risk patients and result in an estimated increase of $25,000, per case, in hospital expenses.  

Clinical Value of the MediPines Gas Exchange Monitor (AGM100 ®)

A leading academic medical center director stated, “Quite frankly, over 15% of our surgical patients have COPD and many more don’t know they have respiratory issues. That is why we are using the MediPines Gas Exchange Monitor (AGM100) to efficiently help screen and risk stratify these patients, before surgery.”

Built on MediPines’ innovative technology and on respiratory concepts pioneered by Dr. John B. West, a world-renowned respiratory physiologist, the AGM100:

  • Provides a fast, objective measure of pulmonary gas exchange.
  • Provides unique and innovative measurements of Oxygen Deficit, calculated arterial blood oxygen level (gPaO2™), PETCO2, and other valuable parameters and indices.
  • Provides results in under 2 minutes from a patient’s normal breathing sample.
  • Is portable, noninvasive, and designed for point-of-care settings.
  • Is ideally suited for high throughput environments, such as the pre-operative evaluation area.

How Can the AGM100 ® Improve Practice?

“This device is as much about empowering patients as it is about empowering clinicians. It allows patients to make more informed decisions about their care choices and provides a better opportunity for patients and clinicians to have matching expectations about surgical risks,” stated Richard Hinds, MediPines’ Medical Director.

Clinicians across the country face growing surgical workloads and have limited time to evaluate a patient’s respiratory status. In the backdrop of outcome-based evaluation in healthcare, reducing post-operative pulmonary complications is a high-value priority for clinicians and hospital providers.

“We are very excited about partnering with leading hospitals on both coasts and providing clinicians with a more complete picture of a patient’s pre-surgical respiratory status, intended to improve patient outcomes,” stated Steve Lee, MediPines CEO.

To schedule a meeting tailored to your clinical situation and needs, and to learn more about how the AGM100® can benefit your practice, click here.

About MediPines:

MediPines Corporation, based in Orange County, California, and manufacturer of the FDA 510(k) cleared MediPines Gas Exchange Monitor®, is a pioneering medical device company established to advance respiratory medicine. For more information, visit https://medipines.com.  

SOURCE MediPines

https://www.prnewswire.com/news-releases/medipines-agm100-launched-for-perioperative-screening-at-2-leading-medical-centers-300915304.html?tc=eml_cleartime

Respiratory Physiology – John B. West Lecture Series Launched by UC San Diego School of Medicine and MediPines

17 Jul 2019 Medical

ORANGE COUNTY, Calif., July 17, 2019 /PRNewswire/ — UC San Diego School of Medicine and MediPines Corporation, a medical device company based in Orange County, California announce the establishment of the “John B. West Distinguished Lecture Series in Respiratory Physiology and Pathophysiology” to help advance the field of respiratory medicine. The inaugural lecture will feature noted scholar, Joe G. N. Garcia M.D., from the University of Arizona College of Medicine-Tucson and will take place on July 29th, 2019 at the T. Denny Sanford Medical Education and Telemedicine Center, UC San Diego School of Medicine in La Jolla, California.

This distinguished lecture series, established in honor of Dr. John B. West, will bring together leading respiratory science researchers and physiologists to present their research findings to faculty-physicians within the Division of Pulmonary, Critical Care and Sleep Medicine, as well as other local physicians-scientists and clinicians, for the purpose of understanding the latest research and its impact on respiratory medicine. For more information on the lecture series visit the UC San Diego John B. West Lecture Series page.

Dr. West is a world-renowned respiratory physiologist, who has contributed six decades of invaluable research to the field of respiratory physiology and medicine. He is the author of the widely respected medical textbook West’s Respiratory Physiology: The Essentialsnow in its tenth edition. He is also the creator of a series of YouTube videos on respiratory physiology that have influenced the study and clinical practice of many medical students and practitioners worldwide.

“It is a great privilege to establish this lectureship series in honor of Dr. John B. West and his lasting impact on respiratory physiology,” stated Dr. Jason Yuan, Professor and Director of the Section of Physiology, Division of Pulmonary, Critical Care and Sleep Medicine at UC San Diego. “The field of respiratory physiology requires a multi-disciplinary translational approach to scientific advancement and UC San Diego is uniquely positioned to lead such efforts, as UC San Diego School of Medicine is home to Dr. West and several other renowned scientists in the field of respiratory physiology and pathophysiology.” 

UC San Diego School of Medicine’s Section of Physiology of the Division of Pulmonary, Critical Care and Sleep Medicine is home to several noted scholars:

The American Physiological Society Presidents

  • Dr. John B. West, 1984-85
  • Dr. Shu Chien, 1990-91
  • Dr. Peter Wagner, 2010-11
  • Dr. Kim Barrett, 2013-14

American Thoracic Society (ATS) Presidents

  • Dr. Atul Malhotra, 2015-16
  • Dr. Peter D. Wagner, 2005-06
  • Dr. Kenneth Moser, 1985-86 (Former chief of the Division of Pulmonary and Critical Care Medicine,1929-1997)

In addition, the UC San Diego Section of Physiology is the home of the editorial office for the journal, Pulmonary Circulation (Sage), of which Dr. Jason Yuan is the founding Editor-in-Chief. UC San Diego is a leading research institution and clinical hub dedicated to respiratory physiology and lung disease. 

Advancement in respiratory medicine is a national health priority.  A few years ago, a chronic lung disease, chronic obstructive pulmonary disease (COPD), was the fifth leading cause of death in the US. Today, COPD is the third leading cause of death in the US according to the American Lung Association and it is projected to become the world’s leading cause of death in the next 15 years.

COPD and Respiratory Challenges

  • Approximately 33 million Americans suffer from chronic or acute respiratory illness.
  • Respiratory disease accounts for ten percent of all emergency department visits, according to the Centers for Disease Control and Prevention (CDC).
  • In the United States, the economic cost attributed to COPD is estimated to be about $50 billion a year according to the COPD Foundation.
  • Studies estimate that 328 million people worldwide have COPD and it is expected to become the leading cause of death by 2035.

Unfortunately, respiratory disease has received far too little attention and funding in comparison with other major causes of global morbidity and mortality. The result is that respiratory illness is developing into a major public health crisis.

“It is timely that UC San Diego School of Medicine, a scientific and medical authority, is establishing a global forum to discuss medical advancement in the field of respiratory physiology,” stated Steve Lee, CEO of MediPines. “We need a multifaceted approach to tackle this national problem, including medical advancement, industry innovation, and forward-looking government policy. MediPines is delighted to partner with UC San Diego School of Medicine to launch this all-important lecture series in respiratory physiology and medicine.”

MediPines Corporation was established to advance respiratory medicine and it recently launched a novel respiratory device called the MediPines Gas Exchange Monitor, which is based on UC San Diego’s innovative medical technology.

About MediPines:

MediPines Corporation, based in Orange County, California, and maker of the FDA 510(k) cleared MediPines Gas Exchange Monitor, is a pioneering medical device company established to advance respiratory medicine. For more information, email contact@medipines.com, call (949) 398-4670, or visit https://medipines.com.

SOURCE MediPines

https://www.prnewswire.com/news-releases/respiratory-physiology—john-b-west-lecture-series-launched-by-uc-san-diego-school-of-medicine-and-medipines-300886801.html

FDA Cleared MediPines Gas Exchange Monitor Measures Freedivers’ Lung Efficiency in Ground-Breaking Study

12 Apr 2019 Medical

Successful Study Findings Unveiled by University of British Columbia Researchers at International Conference in Orlando, Florida

PR Newswire

ORANGE COUNTY, Calif., April 12, 2019 /PRNewswire/ — Novel physiologic results on world elite freedivers’ using the non-invasive MediPines Gas Exchange Monitor (https://bit.ly/2YVAG1M) were presented at the Experimental Biology 2019 conference. Dr. Philip Ainslie, Co-Director of the Centre for Heart, Lung and Vascular Health at the University of British Columbia, with his research team, conducted the study in Split, Croatia.

MP DIVER

The recently FDA 510(k) cleared, MediPines Gas Exchange Monitor is a breakthrough, portable respiratory monitoring device invented to provide real-time, clinically actionable data. This ground-breaking technology is transforming the approach to measuring pulmonary gas exchange in a wide variety of clinical settings, relevant for the 33 million patients in the US (350 million globally), who suffer from respiratory disease.

The physiological demands placed on these world-class athletes are tremendous. “The transient stress on their lungs is similar to what is observed in patients who suffer from cardiac and respiratory disease.” It has been challenging, in the past, to assess the consequences of deep dives on pulmonary gas exchange, especially during true field-based conditions. “Measuring oxygen deficit has allowed us to establish the impact of ‘lung squeeze’ on gas exchange inefficiency in elite freedivers,” stated Dr. Philip Ainslie.

Oxygen deficit was developed for detecting gas exchange inefficiency using a simple, non-invasive method.  “Understanding gas exchange inefficiency in respiratory patients is fundamental to improving patient outcomes,” according to Dr. John B. West, the world-renowned physiologist who pioneered the concept.

Freedivers place themselves in extreme conditions, which push the outer limits of human lung physiology and can lead to high oxygen deficit. The device provided rapid feedback to the research team tasked with assessing the freedivers’ gas exchange status. “We hope that our device will continue to aid clinicians by providing patients’ respiratory status rapidly and conveniently in situations where direct gas exchange measurement is either difficult or impossible; the device also has clear application to field-based conditions,” said Steve Lee, CEO of MediPines. 

About MediPines:

MediPines Corporation, based in Orange County, California, is a pioneering medical device company established to advance respiratory medicine. For more information, visit https://www.new.medipines.com/.

For more information about University of British Columbia’s Centre for Heart, Lung and Vascular Health, visit https://chlvh.ok.ubc.ca/.

(PRNewsfoto/MediPines)
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-cleared-medipines-gas-exchange-monitor-measures-freedivers-lung-efficiency-in-ground-breaking-study-300831089.html

SOURCE MediPines

1 2

Search

+